Dashboard Market News Pricing Contact Us
Search 100,000+ stocks...
English EN
Deutsch DE Español ES
Sign Up
Log in
Cynata Therapeutics Ltd banner

Cynata Therapeutics Ltd
ASX:CYP

Watchlist Manager
Cynata Therapeutics Ltd Logo
Cynata Therapeutics Ltd
ASX:CYP
Watchlist
Price: 0.011 AUD Market Closed
Market Cap: AU$2.7m
Write Note Create Alert Ask AI

Wall St Price Targets

CYP Price Targets Summary
Cynata Therapeutics Ltd

There are no price targets for CYP.
CYP Lowest Forecast
Wall Street Target
Not Available
CYP Average Forecast
Wall Street Target
Not Available
CYP Highest Forecast
Wall Street Target
Not Available
Lowest Forecast
Price Target
Not Available
Average Forecast
Price Target
Not Available
Highest Forecast
Price Target
Not Available
Cynata Therapeutics Ltd Competitors:
Price Targets

Revenue
Forecast

-3% / Year
Past Growth
123% / Year
Estimated Growth
Estimates Accuracy
-86%
Average Miss
-3% / Year
Past Growth
123% / Year
Estimated Growth
Estimates Accuracy
-86%
Average Miss

Over the last 13 years, the compound annual growth rate for Revenue has been -3%. The projected CAGR for the next 3 years is 123%.

What are analyst estimates?

Gross Profit
Forecast

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
Gross Profit Forecast
is not available for Cynata Therapeutics Ltd

Operating Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
7%
Average Beat
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
7%
Average Beat

What are analyst estimates?

Pre-Tax Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
29%
Average Beat
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
29%
Average Beat

What are analyst estimates?

Net Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-6%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-6%
Average Miss

What are analyst estimates?

Continue CYP Research

Summary
CYP intrinsic value, competitors valuation, and company profile.
DCF Valuation
CYP stock valuation using Discount Cash Flow valuation method.
Relative Valuation
CYP stock valuation using valuation multiples.
Wall St Estimates
CYP price targets and financial estimates made by Wall Street analysts.
Profitability
Detailed analysis of the company's profitability.
Solvency
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
CYP stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall St Estimates
Profitability
Solvency
Financials
Discount Rate
Other Cynata Therapeutics Ltd listings:
OTC • USD
CYYNF
 F • EUR
51S
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is CYP's stock price target?
Not Available

CYP does not have any price targets made by Wall Street professionals.

What is the Revenue forecast for Cynata Therapeutics Ltd?
Projected CAGR
123%

Over the last 13 years, the compound annual growth rate for Revenue has been -3%. The projected CAGR for the next 3 years is 123%.

Back to Top
ALPHA SPREAD
Follow us
Join 358,200+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Valuation Backtest Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.